insulin glulisine


Also found in: Medical, Wikipedia.

insulin glu·li·sine

 (glo͞o′lĭ-sēn′)
n.
A rapid-acting insulin analog whose amino acid sequence differs from that of human insulin by the substitution of lysine for asparagine and glutamic acid for lysine in the B chain, used in the treatment of type 1 and type 2 diabetes.

[glu(tamic acid) + alteration of lysine.]
References in periodicals archive ?
Rapid-acting insulins (insulin aspart [NovoLog[R]], insulin lispro [Humalog[R]], insulin glulisine [Apidra[R]]) are preferred for mealtime coverage and correction of hyperglycemia (ADA, 2016; Freeland, 2016).
Subcutaneously injected insulin, even the rapid-acting insulin analogs (insulin aspart, insulin glulisine, and insulin lispro), are absorbed slowly enough into systemic circulation that the insulin concentration can remain elevated up to 6 hours after dosing.
2015.Effects of rapid-acting insulin analogues insulin glulisine and insulin aspart on postprandial glycemic excursion with single bout of exercise in patients with type 2 diabetes.
This has been exploited in the genetic engineering of insulin analogues used in rapid-acting insulin preparations (insulin aspart, insulin lispro, and insulin glulisine), which have substitutions or minor alterations in the amino acid sequence relative to human insulin [65].
Scholtz, "Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese nondiabetic subjects," Experimental and Clinical Endocrinology & Diabetes, vol.
Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care.
the addition of rapid-acting insulin glulisine with or without metformin injected once daily at the time of the patient's main meal (basal-plus), or three times daily at meal time (basal-bolus).
The product, which delivers 1 to 30 units per injection, can be used with Lantus (insulin glargine), Apidra (insulin glulisine) or Insuman (recombinant human insulin).
The company said that the study found that using two regimens including Lantus (insulin glargine [rDNA origin] injection) and Apidra (insulin glulisine [rDNA origin] injection) lowered blood glucose levels compared to premixed insulin with less hypoglycaemia and improvement in diabetes-specific quality of life.
is marketing Apidra SoloSTAR (insulin glulisine [rDNA origin] injection), a prefilled disposable pen that contains the rapid-acting insulin analog Apidra.
The Food and Drug Administration approved a new pediatric indication for Apidra (insulin glulisine [rDNA origin] solution for injection).